Author
1 MIN READ
In this video interview, Dr Deborah Rathjen discusses how Bionomics harnesses innovation to enhance the drug pipeline, and the firm’s recent R&D collaboration for the treatment of cognitive dysfunction in Alzheimer’s patients.
This content is provided by OTC Markets and did not involve IR Magazine journalists.
About the event As more investors and corporate communication teams embrace AI, machine learning and emerging technologies to inform their decision making, investor relations professionals are facing a pivotal moment: adapt and lead, or risk falling behind. At this fast-moving stage of adoption, IR teams are asking important questions regarding…
Building trust and driving impact: Redefining investor relations in South East Asia Investor Relations in South East Asia is at a turning point. Regulatory fragmentation, macroeconomic volatility and the growing importance of retail investors require IROs to strategically analyze and reform traditional practices. The ability to deliver transparent, dependable and…
In partnership with WHEN 8.00 am PT / 11.00 am ET / 4.00 pm GMT / 5.00 pm CET DURATION 45 minutes About the event Explore how IR teams can adapt to the rise of passive investing while effectively measuring and communicating their impact. As index funds and ETFs reshape…
Stay informed on critical issues affecting IR teams, gain expert analysis of market trends, buy-side insights, career advice, and more.
Our new tool lets you benchmark your IR program against peers in your region and sector, uncover strengths, and identify areas for growth.
Packed with industry trends and insights that define best-in-class practices across key, practical, and timely aspects of an IRO’s role.
Powered by the world’s largest survey of the buy side, sell side, and IR professionals, discover data-driven insights on running a successful IR program.
